Speed, flexibility and innovation: Rethinking the way biopharma industry operates

A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.